Intractable Rare Dis Res. 2015;4(1):33-38. (DOI: 10.5582/irdr.2014.01034)

Liver transplantation and autoimmune hepatitis.

Tanaka T, Sugawara Y, Kokudo N


Liver Transplantation (LT) is an effective treatment for patients with end-stage liver disease including autoimmune hepatitis (AIH). Indication for LT for AIH does not differ basically from other liver diseases including both acute and chronic types of disease progression, although it is reported to be an infrequent indication for LT worldwide due to the therapeutic advances of immunosuppression. The outcome following LT is feasible, with current patient and graft survival exceeding 75% at 5 years. Recurrent and de-novo AIH posttranslant has also been reported; and this seems to have important clinical implications because its management differs from the standard treatment for allograft rejection. In this review, we discuss the characteristics of AIH, focusing on the indication for LT and issues raised following LT.

KEYWORDS: Autoimmune hepatitis (AIH), liver transplantation, anti-nuclear antibody (ANA), rejection, de-novo AIH

Full Text: